Apogee Therapeutics (NASDAQ: APGE) leaves Nasdaq in AbbVie cash buyout
Apogee Therapeutics (APGE) is being acquired by AbbVie (ABBV) in a $135.11-per-share cash deal. The merger closed on September 3, 2026, with Apogee's stock ceasing to trade on Nasdaq the following day. Shareholders received $135.11 per share, and Apogee became a wholly owned subsidiary of AbbVie.
How this was made
The 30-second read
Why it matters
The transaction provides a definitive exit for Apogee shareholders and adds pipeline assets to AbbVie, potentially enhancing long‑term growth.
Market read
A significant M&A event in the biotech sector with immediate cash distribution and delisting of APGE.
What to watch
Integration risk and possible regulatory scrutiny could delay value realization for AbbVie.
Background
The merger follows AbbVie's strategy to bolster its immunology and oncology pipeline.
Ticker impact
Apogee Therapeutics is being taken private by AbbVie in a cash deal at $135.11 per share, ending its Nasdaq listing.
APGE will close at cash value; no further price movement expected.
The merger is effective Sep 4, 2026 and cash consideration is fixed, removing price risk.
AbbVie is the acquirer, completing the purchase of Apogee Therapeutics through its subsidiary Andor LLC.
ABBV may see modest short‑term pressure from cash outlay but long‑term upside from added assets.
The deal size is material but already priced in; market will watch integration progress.
Market effects
Biotech M&A activity may lift peer valuations as consolidation accelerates.
US biotech sector sees increased deal flow, modest impact on broader market.
Highlights continued consolidation in global pharma industry.
Counterpoint
The cash premium may be insufficient if Apogee's pipeline underperforms, suggesting a potential overvaluation of the deal.
Key entities
- companyApogee Therapeutics
Biotech firm being acquired.
- companyAbbVie Inc.
Acquirer executing the cash buyout.
